



Contents lists available at [ScienceDirect](http://ScienceDirect.com)

International Journal of Infectious Diseases

journal homepage: [www.elsevier.com/locate/ijid](http://www.elsevier.com/locate/ijid)

Medical Imagery

*Histoplasma capsulatum* in the bone marrow of an HIV-infected patient

**Figure 1.** *Histoplasma capsulatum* within histiocytes seen on bone marrow biopsy staining: (A) Wright–Giemsa, (B) Giemsa, (C) periodic acid–Schiff, and (D) Gomori–Grocott.

A 41-year-old man was admitted to the emergency department with a 1-month history of weight loss, intermittent fever, and malaise. Generalized pallor, mild dehydration, and a temperature of 37.5 °C were found on physical examination. Initial blood workup revealed pancytopenia, elevated lactate dehydrogenase, and hypoalbuminemia. A fourth-generation HIV ELISA test was positive. His HIV-1 RNA viral load was 13 800 copies/ml and the CD4+ T-cell count was 3 cells/mm<sup>3</sup>. Urine, blood, and cerebrospinal fluid cultures were without microbiological isolation.

Histopathological analysis of the bone marrow revealed oval-shaped yeast cells within histiocytes, some showing narrow-based budding (Figure 1). *Histoplasma* urine antigen was >25 ng/ml (normal limit <0.5 ng/ml). The diagnosis of

*Histoplasma capsulatum* infection was made. Antifungal therapy with amphotericin B deoxycholate was administered for a 14-day period. Given the successful clinical response, therapy was switched to oral itraconazole 200 mg every 8 h for 3 days. The patient was subsequently discharged with itraconazole 200 mg every 12 h indefinitely. Highly active antiretroviral therapy was started a week later following an appointment at an HIV outpatient clinic.

The detection of *H. capsulatum* polysaccharide antigen in HIV-infected patients has a 95–100% sensitivity in urine and 92–100% sensitivity in serum (Connolly et al., 2007). False-positive antigen tests have been reported in cases of *Penicillium marneffe* infection, blastomycosis, and paracoccidioidomycosis (Hage et al., 2011).

<http://dx.doi.org/10.1016/j.ijid.2017.06.018>

1201-9712/© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Bone marrow aspirate analyzed by an experienced operator can contribute to the differential diagnosis (Adenis et al., 2014). Identification by culture is the gold standard, with 85–90% sensitivity and 100% specificity (Hage et al., 2011; Couppie et al., 2006). The primary therapy recommended is liposomal amphotericin B; unfortunately its high cost makes it unaffordable in many developing countries. Amphotericin B deoxycholate is an accessible treatment option. Oral itraconazole is an alternative oral treatment option and should be prescribed for a 12-month period, or until the CD4+ T-cell count is >150 cells/mm<sup>3</sup> (Couppie et al., 2006; Wheat et al., 2007).

**Funding:** This paper has received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest:** None declared.

## References

- Adenis AA, Aznar C, Couppie P. Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps. *Curr Trop Med Rep* 2014;1:119–28.
- Connolly PA, Durkin MM, Lemonte AM, Hackett EJ, Wheat LJ. Detection of histoplasma antigen by a quantitative enzyme immunoassay. *Clin Vaccine Immunol.* 2007;14(12):1587–91.
- Couppie P, Aznar C, Carme B, Nacher M. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. *Curr Opin Infect Dis.* 2006;19(5):443–9.
- Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. *Clin Infect Dis.* 2011;53(5):448–54.
- Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2007;45:807–25.

Isaí Medina-Piñón<sup>a,\*</sup>

Pedro Hernández-Rodríguez<sup>a</sup>

Silvia Estela Haces-Rodríguez<sup>b</sup>

Luis Arturo Acosta-Calderón<sup>c</sup>

<sup>a</sup>Infectious Diseases Service, Hospital Universitario “Dr. José E. González” and Medical School, Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/N, Monterrey NL, 64460, Mexico

<sup>b</sup>Department of Internal Medicine, Hospital Universitario “Dr. José E. González” and Medical School, Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/N, Monterrey NL, 64460, Mexico

<sup>c</sup>Anatomic Pathology and Cytopathology Department, Hospital Universitario “Dr. José E. González” and Medical School, Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/N, Monterrey NL, 64460, Mexico

\* Corresponding author at: Infectious Diseases Service, Hospital Universitario “Dr. José E. González” Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/N, Monterrey NL, 64460 Mexico. Tel: +52 (81) 83485013. E-mail address: [isai\\_med@hotmail.com](mailto:isai_med@hotmail.com) (I. Medina-Piñón).

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Received 20 May 2017

Received in revised form 9 June 2017

Accepted 16 June 2017